TherapeuticsMD Inc. [NASDAQ: TXMD] price plunged by -0.96 percent to reach at -$0.01. The company report on December 10, 2021 that U.S. Food and Drug Administration (FDA) Responds to Request From TherapeuticsMD to Revise Certain Manufacturing Testing Limits for ANNOVERA®.
– FDA determined that it could not approve proposed revisions to the manufacturing testing limits requested through the Supplemental New Drug Application (sNDA) — FDA provided recommendations and requested additional information to address the issues — The Company will continue to supply ANNOVERA in compliance with the manufacturing testing limits approved in the original NDA -.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
TherapeuticsMD, Inc. (NASDAQ:TXMD) (“TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced that the FDA determined that it could not approve revisions to certain manufacturing testing limits for ANNOVERA through the sNDA previously submitted by the Company. In its complete response letter, the FDA provided recommendations and requested additional information that could support approval of revisions to certain manufacturing testing limits. The Company will continue to manufacture and supply ANNOVERA under the existing approved specifications.
A sum of 4120403 shares traded at recent session while its average daily volume was at 5.91M shares. TherapeuticsMD Inc. shares reached a high of $0.3687 and dropped to a low of $0.35 until finishing in the latest session at $0.36.
The one-year TXMD stock forecast points to a potential upside of 91.69. The average equity rating for TXMD stock is currently 2.00, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on TherapeuticsMD Inc. [TXMD]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TXMD shares is $4.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TXMD stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for TherapeuticsMD Inc. shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on August 07, 2020. The new note on the price target was released on May 19, 2020, representing the official price target for TherapeuticsMD Inc. stock.
The Average True Range (ATR) for TherapeuticsMD Inc. is set at 0.05, with the Price to Sales ratio for TXMD stock in the period of the last 12 months amounting to 1.76.
TXMD Stock Performance Analysis:
TherapeuticsMD Inc. [TXMD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -17.16. With this latest performance, TXMD shares dropped by -19.62% in over the last four-week period, additionally sinking by -64.46% over the last 6 months – not to mention a drop of -73.54% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TXMD stock in for the last two-week period is set at 37.12, with the RSI for the last a single of trading hit 37.03, and the three-weeks RSI is set at 36.83 for TherapeuticsMD Inc. [TXMD]. The present Moving Average for the last 50 days of trading for this stock 0.5113, while it was recorded at 0.3819 for the last single week of trading, and 0.8845 for the last 200 days.
Insight into TherapeuticsMD Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and TherapeuticsMD Inc. [TXMD] shares currently have an operating margin of -239.76 and a Gross Margin at +73.77. TherapeuticsMD Inc.’s Net Margin is presently recorded at -282.90.
Return on Total Capital for TXMD is now -91.74, given the latest momentum, and Return on Invested Capital for the company is -109.45. Additionally, TXMD Total Debt to Total Capital is recorded at 199.50, with Total Debt to Total Assets ending up at 136.90.
Reflecting on the efficiency of the workforce at the company, TherapeuticsMD Inc. [TXMD] managed to generate an average of -$458,810 per employee. Receivables Turnover for the company is 2.29 with a Total Asset Turnover recorded at a value of 0.29.TherapeuticsMD Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.80 and a Current Ratio set at 1.90.
TXMD Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TXMD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for TherapeuticsMD Inc. go to 17.60%.
TherapeuticsMD Inc. [TXMD] Insider Position Details
There are presently around $48 million, or 37.00% of TXMD stock, in the hands of institutional investors. The top three institutional holders of TXMD stocks are: BLACKROCK INC. with ownership of 25,306,542, which is approximately 1.878% of the company’s market cap and around 0.80% of the total institutional ownership; VANGUARD GROUP INC, holding 18,910,787 shares of the stock with an approximate value of $6.85 million in TXMD stocks shares; and FMR LLC, currently with $5.05 million in TXMD stock with ownership of nearly 0.357% of the company’s market capitalization.
Positions in TherapeuticsMD Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 73 institutional holders increased their position in TherapeuticsMD Inc. [NASDAQ:TXMD] by around 11,783,266 shares. Additionally, 58 investors decreased positions by around 47,171,464 shares, while 44 investors held positions by with 74,242,060 shares. The mentioned changes placed institutional holdings at 133,196,790 shares, according to the latest SEC report filing. TXMD stock had 22 new institutional investments in for a total of 3,966,006 shares, while 24 institutional investors sold positions of 19,279,462 shares during the same period.